Aquestive Therapeutics, Inc. (AQST)
| Previous Close | 3.3650 |
| Open | 3.4000 |
| Bid | 3.2200 x 400 |
| Ask | 3.2900 x 400 |
| Day's Range | 3.2250 - 3.4099 |
| 52 Week Range | 1.2510 - 6.2300 |
| Volume | |
| Avg. Volume | 2,839,408 |
| Market Cap | 296.239M |
| Beta (5Y Monthly) | 2.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.13 |
ZacksAnalysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireAquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of ageCompany track record now includes 4 FDA approvals since 2018Anaphylm program on track; NDA submission expected by the end of 2024Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE)
- GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
WARREN, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2024 and provide an update on recent developments in its business after market close on Tuesday, May 7, 2024. Management will host a conference
